<DOC>
	<DOCNO>NCT00539630</DOCNO>
	<brief_summary>To describe clinical response rate two group ( Docetaxel plus cisplatin plus 5-FU , versus Cisplatin plus 5-FU ) 3 cycle neoadjuvant chemotherapy .</brief_summary>
	<brief_title>TAX + Cisplatin + 5 F/U v Cisplatin + 5 F/U SCCHN</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<criteria>Histologically cytologically proven squamous cell carcinoma head neck locally advance inoperable disease . Primary tumor site eligible : oral cavity , oropharynx , hypopharynx , larynx nasopharynx . Patients require least one ( bior unidimensionally ) measurable lesion . WHO performance status 0 1 . Adequate bone marrow , hepatic renal function . Pregnant lactate woman Previous chemotherapy Previous radiotherapy H &amp; N Previous surgery H &amp; N The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>